Michael Rosenblatt

Michael Rosenblatt, M.D. is the Executive vice president and chief medical officer of Merck & Co., Inc. since 2009. Dr. Rosenblatt served as Dean of Tufts University School of Medicine. Previously, he held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center (BIDMC). He served as the President of BIDMC from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for academic programs at CareGroup and BIDMC and a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and BIDMC, a joint venture whose mission is to manage the academic enterprise and promote academic innovation. Prior to that, he served as Director of the Harvard-MIT Division of Health Sciences and Technology, during which time he led a medical education organization for M.D., Ph.D., and M.D.-Ph.D. training jointly sponsored by Harvard and MIT. Earlier, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology and calcium metabolism, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy. In leading most of Merck's international research efforts, he established two major basic research institutes, one in Tsukuba, Japan, and one near Rome, Italy. He also headed Merck Research's worldwide University and Industry Relations Department.